Design of Pyridopyrazine-1,6-dione γ-Secretase Modulators that Align Potency, MDR Efflux Ratio, and Metabolic Stability
作者:Martin Pettersson、Douglas S. Johnson、John M. Humphrey、Todd W. Butler、Christopher W. am Ende、Benjamin A. Fish、Michael E. Green、Gregory W. Kauffman、Patrick B. Mullins、Christopher J. O’Donnell、Antonia F. Stepan、Cory M. Stiff、Chakrapani Subramanyam、Tuan P. Tran、Beth Cooper Vetelino、Eddie Yang、Longfei Xie、Kelly R. Bales、Leslie R. Pustilnik、Stefanus J. Steyn、Kathleen M. Wood、Patrick R. Verhoest
DOI:10.1021/acsmedchemlett.5b00070
日期:2015.5.14
Herein we describe the design and synthesis of a series of pyridopyrazine-1,6-dione gamma-secretase modulators (GSMs) for Alzheimer's disease (AD) that achieve good alignment of potency, metabolic stability, and low MDR efflux ratios, while also maintaining favorable physicochemical properties. Specifically, incorporation of fluorine enabled design of metabolically less liable lipophilic alkyl substituents to increase potency without compromising the sp(3)-character. The lead compound 21 (PF-06442609) displayed a favorable rodent pharmacokinetic profile, and robust reductions of brain A beta 42 and A beta 40 were observed in a guinea pig time-course experiment.